Bob A Lubamba1, Lisa C Jones1, Wanda K O'Neal1,2, Richard C Boucher1,2, Carla M P Ribeiro1,2,3. 1. 1 Marsico Lung Institute/Cystic Fibrosis Research Center. 2. 2 Department of Medicine, and. 3. 3 Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
RATIONALE: Alveolar macrophages (AMs) play a key role in host defense to inhaled bacterial pathogens, in part by secreting inflammatory mediators. Cystic fibrosis (CF) airways exhibit a persistent, robust inflammatory response that may contribute to the pathophysiology of CF. Recent findings have linked endoplasmic reticulum stress responses mediated by inositol-requiring enzyme 1α-dependent messenger RNA splicing (activation) of X-box-binding protein-1 (XBP-1s) to inflammation in peripheral macrophages. However, the role of XBP-1s in CF AM function is not known. OBJECTIVES: To evaluate inflammatory responses of AMs from chronically infected/inflamed human CF lungs and test whether XBP-1s is required for AM-mediated inflammation. METHODS: Basal and LPS-induced inflammatory responses were evaluated in primary cultures of non-CF versus CF AMs. XBP-1s was measured and its function was evaluated in AMs using 8-formyl-7-hydroxy-4-methylcoumarin (4μ8C), an inhibitor of inositol-requiring enzyme 1α-dependent XBP-1s, and in THP-1 cells stably expressing XBP-1 shRNA, XBP-1s, or a dominant-negative XBP-1. MEASUREMENTS AND MAIN RESULTS: CF AMs exhibited exaggerated basal and LPS-induced production of tumor necrosis factor-α and IL-6, and these responses were coupled to increased levels of XBP-1s. In non-CF and CF AMs, LPS-induced cytokine production was blunted by 4µ8C. A role for XBP-1s in AM inflammatory responses was further established by data from dTHP-1 cells indicating that expression of XBP-1 shRNA reduced XBP-1s levels and LPS-induced inflammatory responses; and LPS-induced inflammation was up-regulated by expression of XBP-1s and inhibited by dominant-negative XBP-1. CONCLUSIONS: These findings suggest that AMs contribute to the robust inflammation of CF airways via an up-regulation of XBP-1s-mediated cytokine production.
RATIONALE: Alveolar macrophages (AMs) play a key role in host defense to inhaled bacterial pathogens, in part by secreting inflammatory mediators. Cystic fibrosis (CF) airways exhibit a persistent, robust inflammatory response that may contribute to the pathophysiology of CF. Recent findings have linked endoplasmic reticulum stress responses mediated by inositol-requiring enzyme 1α-dependent messenger RNA splicing (activation) of X-box-binding protein-1 (XBP-1s) to inflammation in peripheral macrophages. However, the role of XBP-1s in CF AM function is not known. OBJECTIVES: To evaluate inflammatory responses of AMs from chronically infected/inflamed human CF lungs and test whether XBP-1s is required for AM-mediated inflammation. METHODS: Basal and LPS-induced inflammatory responses were evaluated in primary cultures of non-CF versus CF AMs. XBP-1s was measured and its function was evaluated in AMs using 8-formyl-7-hydroxy-4-methylcoumarin (4μ8C), an inhibitor of inositol-requiring enzyme 1α-dependent XBP-1s, and in THP-1 cells stably expressing XBP-1 shRNA, XBP-1s, or a dominant-negative XBP-1. MEASUREMENTS AND MAIN RESULTS: CF AMs exhibited exaggerated basal and LPS-induced production of tumor necrosis factor-α and IL-6, and these responses were coupled to increased levels of XBP-1s. In non-CF and CF AMs, LPS-induced cytokine production was blunted by 4µ8C. A role for XBP-1s in AM inflammatory responses was further established by data from dTHP-1 cells indicating that expression of XBP-1 shRNA reduced XBP-1s levels and LPS-induced inflammatory responses; and LPS-induced inflammation was up-regulated by expression of XBP-1s and inhibited by dominant-negative XBP-1. CONCLUSIONS: These findings suggest that AMs contribute to the robust inflammation of CF airways via an up-regulation of XBP-1s-mediated cytokine production.
Authors: Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman Journal: J Clin Invest Date: 2002-12 Impact factor: 14.808
Authors: T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger Journal: Am J Respir Crit Care Med Date: 1995-12 Impact factor: 21.405
Authors: Behzad Kharabi Masouleh; Huimin Geng; Christian Hurtz; Lai N Chan; Aaron C Logan; Mi Sook Chang; Chuanxin Huang; Srividya Swaminathan; Haibo Sun; Elisabeth Paietta; Ari M Melnick; Phillip Koeffler; Markus Müschen Journal: Proc Natl Acad Sci U S A Date: 2014-05-12 Impact factor: 11.205
Authors: Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal Journal: PLoS One Date: 2009-06-05 Impact factor: 3.240
Authors: Jalahalli M Siddesha; Emily M Nakada; Bethany R Mihavics; Sidra M Hoffman; Gurkiranjit K Rattu; Nicolas Chamberlain; Jonathon M Cahoon; Karolyn G Lahue; Nirav Daphtary; Minara Aliyeva; David G Chapman; Dhimant H Desai; Matthew E Poynter; Vikas Anathy Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-05-06 Impact factor: 5.464
Authors: Brahmchetna Bedi; Kuo-Chuan Lin; Nicholas M Maurice; Zhihong Yuan; Kaiser Bijli; Michael Koval; C Michael Hart; Joanna B Goldberg; Arlene Stecenko; Ruxana T Sadikot Journal: Clin Sci (Lond) Date: 2020-07-31 Impact factor: 6.124
Authors: Osric A Forrest; Sarah A Ingersoll; Marcela K Preininger; Julie Laval; Dominique H Limoli; Milton R Brown; Frances E Lee; Brahmchetna Bedi; Ruxana T Sadikot; Joanna B Goldberg; Vin Tangpricha; Amit Gaggar; Rabindra Tirouvanziam Journal: J Leukoc Biol Date: 2018-05-09 Impact factor: 4.962
Authors: Caterina Di Pietro; Ping-Xia Zhang; Timothy K O'Rourke; Thomas S Murray; Lin Wang; Clemente J Britto; Jonathan L Koff; Diane S Krause; Marie E Egan; Emanuela M Bruscia Journal: Sci Rep Date: 2017-09-07 Impact factor: 4.379
Authors: M Flori Sassano; Eric S Davis; James E Keating; Bryan T Zorn; Tavleen K Kochar; Matthew C Wolfgang; Gary L Glish; Robert Tarran Journal: PLoS Biol Date: 2018-03-27 Impact factor: 8.029